Business
DarioHealth® Presents New Clinical Study Outcomes Showing the Dario Digital Therapeutics Platform Helps Insulin Dependent Patients With Diabetes Better Manage Their Chronic Condition
Patients Significantly Reduced Hypoglycemic and High Glycemic Events by 50% and 40%, respectively, over a Two-Year Period NEW YORK, Feb. 19, 2020 /PRNewswire/
About this update from Dariohealth Corp.
[{"type":"text","content":"Patients Significantly Reduced Hypoglycemic and High Glycemic Events by 50% and 40%, respectively, over a Two-Year Period\n\n\nNEW YORK, Feb. 19, 2020 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (\"DarioHealth\" or \"Dario\"), a pioneer in the global digital therapeutics market, today presented a new clinical study at the Advanced Technologies & Treatments for Diabetes (\"ATTD\") conference in Madrid, Spain, which showed significant reductions of both hypoglycemic and high glycemic events in people with type 1 and insulin dependent type 2 diabetes using Dario's digital therapeutics platform. The presentation will be available at the conference, on the ATTD 2020 website during the conference, and online for one year following the conference. The accepted abstract will be published in the peer-reviewed journal Diabetes Technology & Therapeutics.\nDario's platform delivers evidence-based therapeutic interventions that are driven by precision data analytics, high quality software, and personalized digital coaching. Dario offers a digital blood glucose monitoring platform accessible through its mobile phone app, weekly progress reports, personalized coaching guidance for individual users, feedback alerts, relevant content delivery and follow-up with dedicated professionals via in-app chats features, emails and calls. The platform helps users understand their real-time clinical status, the cause and effect of different behaviors and how to best manage better their condition and potentially improve their clinical outcomes.\nThe clinical study presented at the ATTD conference included data from users enrolled in Dario's full membership plan, which is available to payers, provides and consumers online and in selected physical retail stores.\nThe results of the study show that providing patients with real-time actionable information about their current blood glucose levels, along with alerts when blood glucose values exceed or fall below specified thresholds, can significantly affect the rate of extreme blood glucose events. \nThe Dario study was based on retrospective data analysis of 1,481 insulin dependent users with type 1 or type 2 diabetes evaluated for two years of continuous system use. The baseline was established using the Dario study group users' blood glucose levels at the first month. Once the study began, the average nu...